Finnish type amyloidosis

Finnish type amyloidosis is a rare inherited condition also known by many other names, including MERETOJA syndrome and gelsolin amyloidosis. This condition is linked to abnormalities in a protein called gelsolin, which is produced by the GSN gene. In people with this condition, abnormal protein deposits, known as amyloid, can build up in various tissues of the body. Although detailed information is limited, the disease is recognized as a distinct form of hereditary amyloidosis with a particular genetic background. Many of the details about how Finnish type amyloidosis develops and affects the body are still under study. Researchers use genetic information and the different synonyms to learn more about the condition and its impacts. Information provided from trusted sources such as OMIM and known gene data offers a starting point for understanding this rare disease.

Information about symptoms is currently limited for this condition.

Finnish type amyloidosis is caused by mutations in the GSN gene. Changes in this gene affect the gelsolin protein, which may lead to the buildup of abnormal protein deposits in body tissues. Detailed risk factors and causes beyond the genetic mutation are not fully described in the available sources.

Information about treatment is currently limited for this condition.

Information about prognosis is currently limited for this condition.

Information about current research and future directions is currently limited for this condition.